What Attributes of Emerging Therapies Will Most Influence Both Physicians’ and Payers’ Decisions to Effectively Position These Biologics Against IV Belimumab? Systemic lupus erythematosus (SLE…
How Are Payers Reacting to Elevated Costs and How Will the Cost Trend Impact Specific Brands? The nation’s healthcare payers are using multilayered cost and utilization control strategies to rein…
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
Historically, developers of systemic lupus erythematosus (SLE) drugs faced formidable challenges: drug development and regulatory hurdles, a small and heterogeneous population, and a multiplicity…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organ systems, manifesting at various levels of severity, and involving periods of remission and relapse. The…
Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50 years, but also the first biologic approved for the indication. However, uptake…
Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…
Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment Systemic lupus erythematosus (SLE) is a complex…